Beti-cel gene therapy for transfusion-dependent β-thalassemia: 7-year follow up data
Benefits of beti-cel gene therapy for transfusion-dependent β-thalassemiaПодробнее
Toxicity of beti-cel in transfusion-dependent β-thalassemiaПодробнее
Long-term outcomes of patients with TDT treated with beti-celПодробнее
Past, present, and future management strategies for non-transfusion dependent β-thalassemiaПодробнее
Gene Therapy Treatment for Thalassemia WebinarПодробнее
TCT highlights: long-term outcomes of beti-cel gene therapy for β-thalassemiaПодробнее
Life-Changing Gene Therapy for Beta-Thalassemia Patients with Jennifer Schneiderman, MDПодробнее
Beta-Thalassemia: Progress in clinical Gene Therapy Dr Ashutosh LalПодробнее
Overcoming Treatment Challenges in Beta Thalassemia: Post Activity Q&AПодробнее
The Potential for Gene Therapy in Beta-ThalassemiaПодробнее
Overview & Novel Therapies: Thalassemia, and Other Inherited AnemiasПодробнее
Overcoming Treatment Challenges in Beta ThalassemiaПодробнее
The selection of patients with transfusion-dependent thalassemia for alloSCT or gene therapyПодробнее
Management of patients with thalassemia who cannot undergo HSCT or gene therapyПодробнее
Thalassemia, and Other Inherited Anemias: Overview and Novel TherapiesПодробнее
Overview: Novel Therapies in ThalassemiaПодробнее
ASH 2022: Long-Term PROs Following Treatment with betibeglogene autotemcel in Patients with Tran...Подробнее
Beta thalassemia Current & Future Treatment ApproachesПодробнее
Treating transfusion dependent and independent beta-thalassemia, and BELIEVE/BEYOND trial updatesПодробнее
